StockMarketWire.com - Shield Therapeutics said it would present positive study results for its iron deficiency treatment at in Hamburg on Tuesday.

The presentation would be held as part of United European Gastroenterology Week.

Headline data were previously announced in March.

'This data shows not only that physiological oral iron replacement with Feraccru can produce a similar response rate to IV iron at 12 weeks, but that Feraccru is effective and well tolerated over 52 weeks, even in patients who have been unable to tolerate oral iron salts previously,' chief medical officer Mark Sampson said.


At 9:40am: [LON:STX] Shield Therapeutics Plc share price was +2p at 184.5p



Story provided by StockMarketWire.com